StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) company profile

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

About Iovance Biotherapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Iovance Biotherapeutics is a commercial-stage biotechnology company that develops and delivers individualized tumor-infiltrating lymphocyte cell therapies for patients with solid tumor cancers. Its primary commercial offerings are Amtagvi, a one-time T-cell therapy for adults with advanced melanoma who have undergone prior treatments, and Proleukin, an injectable interleukin-2 medication utilized in cancer treatment regimens and cellular manufacturing. The company distributes its therapies and pharmaceutical products to specialized authorized treatment centers, healthcare professionals, commercial medicine distributors, and biomedical research institutions treating adult oncology patients.

The organization operates a centralized manufacturing site, the Iovance Cell Therapy Center, situated in Philadelphia, Pennsylvania, which possesses an annual production capacity exceeding five thousand patient treatments. To date, treatments manufactured through these proprietary processes have served more than fifteen hundred patients. Geographically, the business delivers cellular therapies across North America, Europe, and the Asia-Pacific region. Its lead product holds regulatory clearance in the United States and Canada, while its secondary product is approved domestically and licensed across multiple international markets.

Summary of the business section of Iovance Biotherapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Iovance Biotherapeutics, Inc.
Founded
2007
Headquarters
San Carlos, CA
Address
825 Industrial Road, 4th Floor 94070
Phone
(650) 260-7120
Employees
975, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
IOVA
Former tickers
LBIO until Aug 3, 2017
Exchange
Nasdaq
Shares outstanding
453M, Jul 29, 2026
Public float
$534.80M, Jun 30, 2025
Filer category
Accelerated filer
Stock splits
1-for-100 reverse, Sep 26, 2013
SEC CIK
1425205
CUSIP
462260100
ISIN
US4622601007
FIGI
BBG000FTLBV7
Share class FIGI
BBG001T2PM32
LEI
2549002L8WT2ACU5Q878
EIN
75-3254381

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Frederick G. VogtInterim CEO & General Counsel, Director604,144
Daniel Gordon KirbyChief Commercial Officer160,576
Corleen M. RocheChief Financial Officer35,946
Noah BerkowitzChief Medical Officer–
Raj K. PuriChief Regulatory Officer260,842
Igor BilinskyChief Operating Officer142,074
Finckenstein Friedrich GrafChief Medical Officer144,087
Matthew W. RosinackSVP, Finance (Int. PFO & PAO)89,129
Jean-Marc BelleminChief Financial Officer64,993
Michael WeiserDirector133,303
Iain D. DukesDirector54,000
Ryan D. MaynardDirector57,500
Athena CountouriotisDirector–
Wendy L. YarnoDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.89M-$1.62M$1.29M$6$125
FY2024$10.95M$7.05M$3.26M$27$118
FY2023$4.79M$5.22M$1.69M$29$119
FY2022$5.26M-$173.21K$2.16M$23$114
FY2021
Frederick GVogt
$3.22M$3.17M$3.27M$69$126
FY2021
Maria Fardis
$7.01M-$2.48M$3.27M$69$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Frederick G. Vogt
Interim Chief Executive Officer and President, General Counsel
$800.00K–$759.38K–$312.00K$16.80K$1.89M-83%
Corleen Roche
Chief Financial Officer
$243.29K$50.00K$387.00K$574.83K$194.40K$6.46K$1.46M–
Daniel Kirby
Chief Commercial Officer
$507.53K$100.00K$1.22M$133.76K$184.68K$11.82K$2.16M–
Raj K. Puri
Chief Regulatory Officer
$671.94K–$474.62K–$181.42K$13.80K$1.34M-58%
Igor Bilinsky
Chief Operating Officer
$570.53K–$379.69K–$154.04K$13.80K$1.12M-66%
Jean-Marc Bellemin
Former Chief Financial Officer
$277.45K–$379.69K––$5.96K$663.10K-80%
Matthew W. Rosinack
Interim Principal Financial Officer and Principal Accounting Officer
$433.51K$18.75K$239.19K–$91.04K–$782.49K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 975 employees, 775 of whom were engaged in research and development, and commercial manufacturing activities, and 200 of whom were engaged in general and administrative support activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 18, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 12, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 5, 2017Name changeName changed from Lion Biotechnologies, Inc. to Iovance Biotherapeutics, Inc.
Apr 7, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 25, 2015ListingRegistration of securities on an exchange (Form 8-A)
Sep 23, 2013Name changeName changed from Genesis Biopharma, Inc to Lion Biotechnologies, Inc.
Aug 15, 2013Late filingNotification of late filing
Apr 1, 2013Late filingNotification of late filing
Nov 13, 2012Late filingNotification of late filing
Aug 10, 2012Late filingNotification of late filing
May 11, 2012Late filingNotification of late filing
Mar 15, 2012Late filingNotification of late filing
Mar 6, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 15, 2011Late filingNotification of late filing
Aug 16, 2011Late filingNotification of late filing
May 16, 2011Late filingNotification of late filing
Apr 1, 2011Late filingNotification of late filing
Nov 16, 2010Late filingNotification of late filing
Jul 6, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 19, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 8, 2010Name changeName changed from FREIGHT MANAGEMENT CORP to Genesis Biopharma, Inc
Mar 8, 2010Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 16, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 25, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 6, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)

See a number that looks wrong?